Sol-Gel Technologies Ltd(SLGL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.64 | Insider Own | 59.73% | Shs Outstand | 3.3M | Perf Week | 1.88% |
| Market Cap | 0.22B | Forward P/E | - | EPS next Y | -16.88% | Insider Trans | 3.44% | Shs Float | 1.3M | Perf Month | -7.57% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -2.07 | Inst Own | 46.71% | Short Float | 10.32% | Perf Quarter | -16.52% |
| Income | -0.02B | P/S | 125.58 | EPS this Y | -253.14% | Inst Trans | 9.47% | Short Ratio | 2.51 | Perf Half Y | -7.27% |
| Sales | 0.00B | P/B | 4.67 | EPS next 5Y | - | ROA | -35.11% | Short Interest | 0.14M | Perf YTD | 62.93% |
| Book/sh | 14.69 | P/C | 4.69 | EPS past 3/5Y | 30.15% 29.88% | ROE | -40.85% | 52W High | -29.92% ($97.97) | Perf Year | 85.57% |
| Cash/sh | 14.64 | P/FCF | - | Sales past 3/5Y | 70.92% 17.19% | ROIC | -33.79% | 52W Low | 138.32% ($28.81) | Perf 3Y | 416.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -361.11% | Gross Margin | - | Volatility(W/M) | 5.36% 6.08% | Perf 5Y | -23.71% |
| Dividend TTM | - | EV/Sales | 99.24 | Sales Y/Y TTM | -92.5% | Oper. Margin | -989.97% | ATR (14) | 4.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.37 | EPS Q/Q | -127.01% | Profit Margin | -910.14% | RSI (14) | 49.51 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.37 | Sales Q/Q | -96.58% | SMA20 | -1.34% ($69.59) | Beta | 1.25 | Target Price | $152.5 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/20 | SMA50 | -0.84% ($69.24) | Rel Volume | 0.46 | Prev Close | $68.18 |
| Employees | 28 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 52.12% 688% | SMA200 | -7.25% ($74.03) | Avg Volume(3M) | 0.05M | Price | $68.66 |
| IPO | 2018/2/1 | Option/Short | No/Yes | Trades | 434 | Volume | 24,771 | Change | 0.7% |
Sol-Gel Technologies (SLGL) is a clinical-stage specialty pharmaceutical and biotech company focused on the dermatology field. Headquartered in Israel, the company is a biotech firm that primarily develops a novel drug pipeline for rare skin diseases, with a foundation in treatments for acne and rosacea.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded less than usual. That is 46% of its average volume.
SLGL has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -253.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $12,558. Peers typically go for $1,089.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -23.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 46.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IZRL ARK Israel Innovative Technology ETF 0.02% It ranks #293 of 594 in the industry
Based on market cap of $225M.
IKT#290 Inhibikase Therapeutics Inc $233M PER - 
PYXS#291 Pyxis Oncology Inc $226M PER - 
KROS#292 Keros Therapeutics Inc $225M PER - SLGL#293 Sol-Gel Technologies Ltd $225M PER - 
BBOT#294 BridgeBio Oncology Therapeutics Inc $216M PER - 
FAQ
What kind of company is SLGL?
SLGL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SLGL?
The market cap of SLGL is approximately $225M, ranking 3,937 within its sector.
What is the 52-week high and low for SLGL?
SLGL has recorded a 52-week high of $97.97 and a low of $28.81.
